NYSE : EVMN
Evommune, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 6.73 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 244.25M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Evommune, Inc. (EVMN) reported revenue of 10.00M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | 10.00M | 13.00M | 7.00M | 5.00M |
| Gross Profit | 10.00M | 13.00M | 7.00M | 5.00M |
| Selling, General & Admin | 28.12M | 20.03M | 12.77M | 10.85M |
| Research & Development | 83.77M | 74.04M | 64.24M | 32.00M |
| Operating Expenses | 111.89M | 94.07M | 77.01M | 42.85M |
| Operating Income | -101.89M | -81.07M | -70.01M | -37.85M |
| Interest Expense | -7.00K | -34.00K | -58.00K | |
| Interest & Investment Income | 7.24M | 3.32M | 3.24M | 3.86M |
| Other Non Operating Income (Expenses) | -15.00K | 8.88M | -3.00K | -1.00K |
| Pretax Income | -94.67M | -68.87M | -66.81M | -34.05M |
| Net Income | -94.67M | -68.87M | -66.81M | -34.05M |
| Preferred Dividends & Other Adjustments | 1.50M | |||
| Net Income to Common | -94.67M | -68.87M | -68.31M | -34.05M |
| Shares Outstanding (Basic) | 22.82M | 6.14M | 1.51M | 1.25M |
| Shares Outstanding (Diluted) | 22.82M | 6.14M | 1.51M | 1.25M |
| EPS (Basic) | -4.15 | -11.22 | -45.29 | -27.17 |
| EPS (Diluted) | -4.15 | -11.22 | -45.29 | -27.17 |
| Free Cash Flow | -74.65M | -76.68M | -58.28M | -30.09M |
| Free Cash Flow Per Share | -3.27 | -12.49 | -38.64 | -24.01 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -1,018.94% | -623.62% | -1,000.19% | -757.00% |
| Profit Margin | -946.68% | -529.77% | -975.83% | -681.06% |
| Free Cash Flow Margin | -746.54% | -589.82% | -832.61% | -601.76% |
| EBITDA | -100.36M | -79.68M | -68.73M | -36.85M |
| D&A For EBITDA | 1.54M | 1.39M | 1.29M | 1.00M |
| EBIT | -101.89M | -81.07M | -70.01M | -37.85M |
| Revenue as Reported | 10.00M | 13.00M | 7.00M | 5.00M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 60.03M | 44.06M | 16.25M | 29.02M |
| Short-Term Investments | 140.76M | 105.14M | 55.78M | 50.06M |
| Cash & Short-Term Investments | 200.79M | 149.20M | 72.04M | 79.08M |
| Prepaid Expenses | 3.45M | 4.28M | 1.95M | 948.00K |
| Total Current Assets | 204.25M | 153.48M | 73.99M | 80.03M |
| Property, Plant & Equipment | 9.22M | 2.46M | 1.80M | 1.97M |
| Long-Term Investments | 87.21M | 67.49M | ||
| Other Long-Term Assets | 1.27M | 1.52M | 269.00K | 252.00K |
| Total Assets | 301.95M | 224.95M | 76.06M | 82.25M |
| Accounts Payable | 5.04M | 7.76M | 8.26M | 1.76M |
| Accrued Expenses | 10.69M | 9.55M | 6.73M | 4.03M |
| Current Portion of Leases | 1.75M | 589.00K | 487.00K | 769.00K |
| Current Unearned Revenue | 3.00M | |||
| Other Current Liabilities | 17.00K | 9.50M | 304.00K | |
| Total Current Liabilities | 17.49M | 17.91M | 27.98M | 6.86M |
| Long-Term Leases | 6.87M | 1.47M | 535.00K | 487.00K |
| Long-Term Deferred Tax Liabilities | 3.00M | |||
| Other Long-Term Liabilities | 245.00K | |||
| Total Liabilities | 24.36M | 19.38M | 28.52M | 10.59M |
| Common Stock | 4.00K | 3.00K | 1.00K | |
| Additional Paid-In Capital | 552.59M | 426.65M | 7.98M | 6.20M |
| Retained Earnings | -275.01M | -221.09M | -152.22M | -83.91M |
| Total Common Equity | 277.59M | 205.57M | -144.24M | -77.71M |
| Shareholders' Equity | 277.59M | 205.57M | 47.54M | 71.66M |
| Total Liabilities & Equity | 301.95M | 224.95M | 76.06M | 82.25M |
| Total Debt | 8.63M | 2.06M | 1.02M | 1.26M |
| Net Cash (Debt) | 192.16M | 147.14M | 71.02M | 77.83M |
| Net Cash Per Share | 8.42 | 23.98 | 47.09 | 62.10 |
| Filing Date Shares Outstanding | 36.29M | 36.02M | 1.55M | 1.25M |
| Total Common Shares Outstanding | 36.28M | 31.52M | 1.55M | 1.25M |
| Working Capital | 186.76M | 135.57M | 46.01M | 73.17M |
| Book Value Per Share | 7.65 | 6.52 | -92.97 | -62.01 |
| Tangible Book Value | 277.59M | 205.57M | -144.24M | -77.71M |
| Tangible Book Value Per Share | 7.65 | 6.52 | -92.97 | -62.01 |
| Machinery | 961.00K | 833.00K | 669.00K | |
| Construction In Progress | 43.00K | 35.00K | ||
| Leasehold Improvements | 542.00K | 528.00K | 458.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -94.67M | -68.87M | -66.81M | -34.05M |
| Depreciation & Amortization | 1.54M | 1.39M | 1.29M | 1.00M |
| Loss (Gain) From Sale of Investments | -2.64M | -1.77M | -1.82M | -1.75M |
| Stock-Based Compensation | 12.81M | 5.86M | 1.72M | 1.48M |
| Other Operating Activities | -8.93M | |||
| Change in Accounts Payable | 988.00K | -837.00K | 6.51M | 125.00K |
| Change in Unearned Revenue | -3.00M | 3.00M | ||
| Change in Other Net Operating Assets | 7.83M | -282.00K | 918.00K | 219.00K |
| Operating Cash Flow | -74.15M | -76.44M | -58.20M | -29.97M |
| Capital Expenditures | -501.00K | -235.00K | -88.00K | -118.00K |
| Investment in Securities | -200.37M | -115.07M | -3.90M | -48.31M |
| Investing Cash Flow | -200.87M | -115.31M | -3.99M | -48.43M |
| Long-Term Debt Repaid | -531.00K | -423.00K | -230.00K | |
| Net Debt Issued (Repaid) | -451.00K | -531.00K | -423.00K | -230.00K |
| Issuance of Common Stock | 275.16M | 157.29M | 13.00K | 5.00K |
| Repurchase of Common Stock | -1.22M | -1.22M | ||
| Financing Cash Flow | 274.22M | 220.76M | 49.42M | 63.75M |
| Net Cash Flow | -808.00K | 29.02M | -12.77M | -14.65M |
| Free Cash Flow | -74.65M | -76.68M | -58.28M | -30.09M |
| Free Cash Flow Margin | -746.54% | -589.82% | -832.61% | -601.76% |
| Free Cash Flow Per Share | -3.27 | -12.49 | -38.64 | -24.01 |
| Levered Free Cash Flow | -39.13M | -56.17M | -20.45M | |
| Unlevered Free Cash Flow | -39.13M | -56.16M | -20.43M | |
| Cash Interest Paid | 4.00K | 7.00K | 34.00K | 58.00K |
| Change in Working Capital | 8.81M | -4.12M | 7.42M | 3.34M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Market Capitalization | 244.25M | 539.69M | ||
| Enterprise Value | 52.08M | 721.40M | ||
| Last Close Price | 6.73 | 17.12 | ||
| PS Ratio | 24.42 | 41.52 | ||
| PB Ratio | 0.88 | 2.62 | ||
| P/TBV Ratio | 0.88 | 2.62 | ||
| EV/Sales Ratio | 5.21 | 55.49 | ||
| Debt / Equity Ratio | 0.03 | 0.01 | 0.02 | 0.02 |
| Net Debt / Equity Ratio | -0.69 | -0.72 | -1.49 | -1.09 |
| Net Debt / EBITDA Ratio | 1.92 | 1.85 | 1.03 | 2.11 |
| Net Debt / FCF Ratio | 2.57 | 1.92 | 1.22 | 2.59 |
| Asset Turnover | 0.05 | 0.09 | 0.09 | |
| Quick Ratio | 11.48 | 8.33 | 2.58 | 11.53 |
| Current Ratio | 11.68 | 8.57 | 2.64 | 11.67 |
| Return on Equity (ROE) | -52.11% | -54.42% | -112.09% | |
| Return on Assets (ROA) | -31.99% | -33.67% | -55.28% | |
| Return on Capital Employed (ROCE) | -35.80% | -39.20% | -145.60% | -50.20% |
| Earnings Yield | -61.64% | -12.76% | ||
| FCF Yield | -30.57% | -14.21% | ||
| Buyback Yield / Dilution | -1,390.45% | -306.86% | -20.35% |